

1/42





FIGURE 1

A



B




FIGURE 2




FIGURE 3

4/42






FIGURE 3 (contd.)

5/42

1252_P01_C08



TS8.2_anti-mouse IgG





FIGURE 3 (contd.)

A)



B)





FIGURE 4

7/42

A)



B)




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9



FIGURE 10




FIGURE 11

12/42

A)




FIGURE 12

13/42

B)




FIGURE 12 (contd.)

14/42

C)




FIGURE 12 (contd.)

15/42

A)




FIGURE 13

16/42

B)




FIGURE 13 (contd.)

17/42

C)




FIGURE 13 (contd.)

18/42

A)




FIGURE 14

19/42

B)




FIGURE 14 (contd.)

20/42

C)




FIGURE 14 (contd.)

21/42

D)




FIGURE 14 (contd.)

22/42

A)




FIGURE 15

B)




FIGURE 15 (contd.)

C)




FIGURE 15 (contd.)

25/42




FIGURE 16

26/42




FIGURE 16 (contd.)

27/42

A)




FIGURE 17

28/42

B)




FIGURE 17 (contd.)

29/42




FIGURE 18

30/42

Expansion after re-seed d17: total cell number




FIGURE 19

31/42




FIGURE 20

32/42




FIGURE 21




FIGURE 22




FIGURE 23





FIGURE 24






FIGURE 25 (contd.)




FIGURE 26

39/42

c)

% improvement in EC50	
No mAb	100%
D1.3 IgG1	109%
1252_P01_C08 IgG1	337%
1245_P02_G04 IgG	383%
1245_P01_E07 IgG	159%

D)

EC50s		
	$\gamma\delta$ T-cell	T:E ratio
No mAb	8729	0.11
D1.3 IgG1	8019	0.12
1252_P01_C08 IgG1	2594	0.39
1245_P02_G04 IgG	2278	0.44
1245_P01_E07 IgG	5485	0.18

FIGURE 26 (contd.)




FIGURE 27

41/42

i

	EC50s		
	γ δT-cell	T:E ratio	% improvement
No mAb	4102	0.24	100%
D1.3 IgG1	3651	0.27	112%
D1.3 IgG LAGA	3640	0.27	113%
E07-LAGA	3229	0.31	127%
D1.3 FS1-67	2794	0.36	147%
Cetuximab	3246	0.31	126%
E07 FS1-67	1581	0.63	259%

J




FIGURE 27 (contd.)

42/42

A)

	EC50s		
	$\gamma\delta$ T-cell	T:E ratio	% improvement
RSV IgG	1988	1.99	100%
G04	2128	2.13	93%
E07	1775	1.78	112%
D1.3 VHVL	1143	1.14	174%
G04 VHVL	470	0.47	423%
E07 VHVL	828	0.83	240%

B)




FIGURE 28